Yaz plus film-coated tablets blister pack 28 pcs

Active ingredients: ethinylestradiol, drospirenone, calcium levomefolate;

1 pack contains 28 tablets (24 pink tablets and 4 light orange tablets);

1 pink tablet contains ethinylestradiol 0.02 mg (in the form of clathrates from betadex) and drospirenone 3 mg, calcium levomefolate 0.451 mg;

Excipients: lactose, microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, magnesium stearate, polyethylene glycol 6000, talc, titanium dioxide (E 171), yellow iron oxide (E 172), red iron oxide (E 172).

1 light orange tablet contains 0.451 mg of calcium levomefolate;

Excipients: lactose, microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, magnesium stearate, polyethylene glycol 6000, talc, titanium dioxide (E 171), yellow iron oxide (E 172), red iron oxide (E 172).

• Kidney dysfunction.
• Adrenal cortex insufficiency.
• High risk of developing arterial or venous thrombosis.
• Abnormal uterine bleeding of unknown etiology.
• Breast cancer or other cancers sensitive to estrogen or progestins, including a history.
• Liver tumors, benign or malignant, or liver disease.
• Pregnancy (due to the lack of need for COC use during pregnancy).
• Use of combination drugs for the treatment of hepatitis C containing ombitasvir/paritaprevir/ritonavir with or without the addition of dasabuvir due to potential elevations in ALT levels.

When combined oral contraceptives (COCs) are used correctly, the failure rate is approximately 1% per year. If pills are missed or used incorrectly, the failure rate may increase.

The tablets should be taken daily in the order indicated on the package, at about the same time, with a small amount of liquid. The drug is taken 1 tablet per day for 28 consecutive days. Taking tablets from each subsequent package should begin the day after taking the last tablet from the package, which has ended.

Bleeding usually begins 2-3 days after starting the light orange, hormone-free tablets (the last row in the pack) and may not end before you start taking the tablets from the next pack.

Pregnant women

Contraindicated.

Children

The drug is indicated for use only after the onset of stable menstruation.

Drivers

Does not affect.

There is no clinical experience of overdose with Yaz Plus tablets. Based on general experience with combined oral contraceptives, overdose may cause nausea, vomiting or, in young girls, vaginal bleeding. There is no specific antidote; treatment should be symptomatic.

The most common side effects when using Yaz Plus for pregnancy prevention and for the treatment of moderate acne are nausea, breast tenderness, uterine and vaginal bleeding. These side effects occurred in more than 3% of patients. The most common side effects when using Yaz Plus for the treatment of premenstrual dysphoric disorder (PMDD) are nausea, breast tenderness, and unscheduled uterine bleeding. These side effects occurred in more than 10% of patients.

Serious adverse reactions include arterial and venous thromboembolism.

Interaction of oral contraceptives and other drugs (enzyme inducers, some antibiotics) may lead to breakthrough bleeding and/or loss of contraceptive efficacy. When treated with any of these drugs, a barrier method should be temporarily used in addition to COCs or another method of contraception. When treated with drugs that induce microsomal enzymes, a barrier method should be used throughout the entire period of treatment with the corresponding drug and for 28 days after its discontinuation.

Store out of the reach of children at a temperature not exceeding 25 °C.

Shelf life – 36 months.